Ultragenyx Pharmaceutical Statistics
Total Valuation
RARE has a market cap or net worth of $4.08 billion. The enterprise value is $4.18 billion.
Important Dates
The next estimated earnings date is Thursday, February 13, 2025, after market close.
Earnings Date | Feb 13, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
RARE has 92.28 million shares outstanding. The number of shares has increased by 22.79% in one year.
Current Share Class | 92.28M |
Shares Outstanding | 92.28M |
Shares Change (YoY) | +22.79% |
Shares Change (QoQ) | +10.30% |
Owned by Insiders (%) | 3.46% |
Owned by Institutions (%) | 95.80% |
Float | 89.04M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 7.35 |
Forward PS | 6.53 |
PB Ratio | 11.76 |
P/TBV Ratio | 29.68 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 8.00 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.81, with a Debt / Equity ratio of 2.58.
Current Ratio | 2.81 |
Quick Ratio | 2.47 |
Debt / Equity | 2.58 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -8.26 |
Financial Efficiency
Return on equity (ROE) is -289.98% and return on invested capital (ROIC) is -29.76%.
Return on Equity (ROE) | -289.98% |
Return on Assets (ROA) | -24.12% |
Return on Capital (ROIC) | -29.76% |
Revenue Per Employee | $409,675 |
Profits Per Employee | -$438,078 |
Employee Count | 1,276 |
Asset Turnover | 0.38 |
Inventory Turnover | 19.17 |
Taxes
Income Tax | -2.09M |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -8.28% in the last 52 weeks. The beta is 0.55, so RARE's price volatility has been lower than the market average.
Beta (5Y) | 0.55 |
52-Week Price Change | -8.28% |
50-Day Moving Average | 49.67 |
200-Day Moving Average | 47.86 |
Relative Strength Index (RSI) | 36.40 |
Average Volume (20 Days) | 717,638 |
Short Selling Information
The latest short interest is 3.38 million, so 3.66% of the outstanding shares have been sold short.
Short Interest | 3.38M |
Short Previous Month | 3.35M |
Short % of Shares Out | 3.66% |
Short % of Float | 3.79% |
Short Ratio (days to cover) | 3.85 |
Income Statement
In the last 12 months, RARE had revenue of $522.75 million and -$558.99 million in losses. Loss per share was -$6.43.
Revenue | 522.75M |
Gross Profit | -197.59M |
Operating Income | -535.74M |
Pretax Income | -586.86M |
Net Income | -558.99M |
EBITDA | -501.06M |
EBIT | -535.74M |
Loss Per Share | -$6.43 |
Full Income Statement Balance Sheet
The company has $607.51 million in cash and $912.50 million in debt, giving a net cash position of -$101.90 million or -$1.10 per share.
Cash & Cash Equivalents | 607.51M |
Total Debt | 912.50M |
Net Cash | -101.90M |
Net Cash Per Share | -$1.10 |
Equity (Book Value) | 353.83M |
Book Value Per Share | 3.76 |
Working Capital | 514.60M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$418.59 million and capital expenditures -$8.44 million, giving a free cash flow of -$427.03 million.
Operating Cash Flow | -418.59M |
Capital Expenditures | -8.44M |
Free Cash Flow | -427.03M |
FCF Per Share | -$4.63 |
Full Cash Flow Statement Margins
Gross margin is -37.80%, with operating and profit margins of -102.49% and -106.93%.
Gross Margin | -37.80% |
Operating Margin | -102.49% |
Pretax Margin | -107.33% |
Profit Margin | -106.93% |
EBITDA Margin | -95.85% |
EBIT Margin | -102.49% |
FCF Margin | n/a |
Dividends & Yields
RARE does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -22.79% |
Shareholder Yield | -22.79% |
Earnings Yield | -13.70% |
FCF Yield | -10.47% |
Dividend Details Analyst Forecast
The average price target for RARE is $88.43, which is 99.98% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $88.43 |
Price Target Difference | 99.98% |
Analyst Consensus | Strong Buy |
Analyst Count | 14 |
Revenue Growth Forecast (5Y) | 37.25% |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
RARE has an Altman Z-Score of -1.96 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -1.96 |
Piotroski F-Score | 4 |